鼻腔内给药:药物开发过程中的机遇和毒理学挑战。
Intranasal drug delivery: opportunities and toxicologic challenges during drug development.
机构信息
Preclinical Safety, AbbVie Deutschland GmbH & Co. KG, Knollstrasse, 67061, Ludwigshafen, Germany.
Department of Pharmacy, Pharmaceutical Technology and Biopharmacy, Ludwig-Maximilians-University, Butenandtstraße 5-13, 81337, Munich, Germany.
出版信息
Drug Deliv Transl Res. 2022 Apr;12(4):735-757. doi: 10.1007/s13346-020-00891-5. Epub 2021 Jan 25.
Over the past 10 years, the interest in intranasal drug delivery in pharmaceutical R&D has increased. This review article summarises information on intranasal administration for local and systemic delivery, as well as for CNS indications. Nasal delivery offers many advantages over standard systemic delivery systems, such as its non-invasive character, a fast onset of action and in many cases reduced side effects due to a more targeted delivery. There are still formulation limitations and toxicological aspects to be optimised. Intranasal drug delivery in the field of drug development is an interesting delivery route for the treatment of neurological disorders. Systemic approaches often fail to efficiently supply the CNS with drugs. This review paper describes the anatomical, histological and physiological basis and summarises currently approved drugs for administration via intranasal delivery. Further, the review focuses on toxicological considerations of intranasally applied compounds and discusses formulation aspects that need to be considered for drug development.
在过去的 10 年中,药物研发领域对鼻腔给药的兴趣日益增加。本文综述了鼻腔给药用于局部和全身给药以及中枢神经系统适应症的信息。与标准的全身给药系统相比,鼻腔给药具有许多优势,例如其非侵入性、起效快,并且在许多情况下由于更靶向的递送而减少了副作用。仍然存在制剂限制和毒理学方面需要优化。在药物开发领域,鼻腔给药是治疗神经紊乱的一种很有前途的给药途径。全身给药方法往往不能有效地将药物输送到中枢神经系统。本文综述了鼻腔给药的解剖学、组织学和生理学基础,并总结了目前批准用于鼻腔给药的药物。此外,本文还重点讨论了鼻腔应用化合物的毒理学考虑因素,并讨论了药物开发中需要考虑的制剂方面。